Effects of Medical Treatment of Prostate Cancer on Bone Health

被引：31
作者：
Formenti, Anna Maria [1 ]
Dalla Volta, Alberto [2 ]
di Filippo, Luigi [1 ]
Berruti, Alfredo [2 ]
Giustina, Andrea [1 ]
机构：
[1] San Raffaele Vita Salute Univ, San Raffaele Hosp, Inst Endocrine & Metab Sci, Ist Ricovero & Cura Carattere Sci IRCCS, Milan, Italy
[2] Univ Brescia, Dept Med & Surg Specialties Radiol Sci & Publ Hlt, Med Oncol, Radiol Sci,Azienda Socio Sanit Terr ASST Spedali, Brescia, Italy
来源：
TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2021年 / 32卷 / 03期
关键词：
ANDROGEN-DEPRIVATION THERAPY; GROWTH-HORMONE-SECRETION; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; RANDOMIZED CONTROLLED-TRIAL; LEAN BODY-MASS; MINERAL DENSITY; VERTEBRAL FRACTURES; TRABECULAR BONE; ZOLEDRONIC ACID; DOUBLE-BLIND;
D O I：
10.1016/j.tem.2020.12.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Medical treatment of prostate cancer (PC) is multidisciplinary, resulting in prolonged survival. Androgen-deprivation therapy (ADT) can have negative effects on skeletal metabolism, particularly if combined with glucocorticoids. We discuss the pathophysiology and effects of ADT and glucocorticoids on skeletal endpoints, as well as the awareness and management of bone fragility. Coadministration of glucocorticoids is necessary with abiraterone because this causes a novel acquired form of 17-hydroxylase deficiency and synergistically increases the risk of fracture by affecting bone quality. Bone antiresorptive agents [selective estrogen receptor modulators (SERMS), bisphosphonates, and denosumab] increase bone mineral density (BMD) and in some instances reduce fracture risk in PC patients on ADT. Awareness and management of bone health in PC can be improved by integrating endocrinologists into the multidisciplinary PC team.
引用
收藏
页码：135 / 158
页数：24
相关论文
共 203 条
[1]   Glucocorticoid-induced osteoporosis: 2019 concise clinical review [J].
Adami, G. ;
Saag, K. G. .
OSTEOPOROSIS INTERNATIONAL, 2019, 30 (06) :1145-1156
[2]   Glucocorticoid-Induced Osteoporosis: Management Challenges in Older Patients [J].
Adler, Robert A. .
JOURNAL OF CLINICAL DENSITOMETRY, 2019, 22 (01) :20-24
[3]   Incidence and risk factors for low trauma fractures in men with prostate cancer [J].
Ahlborg, Henrik G. ;
Nguyen, Nguyen D. ;
Center, Jacqueline R. ;
Eisman, John A. ;
Nguyen, Tuan V. .
BONE, 2008, 43 (03) :556-560
[4]   The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer [J].
Al-Shamsi, Humaid O. ;
Lau, Arthur N. ;
Malik, Kartika ;
Alamri, Abdulaziz ;
Ioannidis, George ;
Corbett, Tom ;
Adachi, J. D. ;
Papaioannou, Alexandra .
JOURNAL OF ONCOLOGY, 2012, 2012
[5]  
Albala C, 1996, INT J OBESITY, V20, P1027
[6]   Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D [J].
Alibhai, S. M. H. ;
Mohamedali, H. Z. ;
Gulamhusein, H. ;
Panju, A. H. ;
Breunis, H. ;
Timilshina, N. ;
Fleshner, N. ;
Krahn, M. D. ;
Naglie, G. ;
Tannock, I. F. ;
Tomlinson, G. ;
Warde, P. ;
Canning, S. Duff ;
Cheung, A. M. .
OSTEOPOROSIS INTERNATIONAL, 2013, 24 (10) :2571-2579
[7]   Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials [J].
Amiche, M. A. ;
Albaum, J. M. ;
Tadrous, M. ;
Pechlivanoglou, P. ;
Levesque, L. E. ;
Adachi, J. D. ;
Cadarette, S. M. .
OSTEOPOROSIS INTERNATIONAL, 2016, 27 (05) :1709-1718
[8]   The role of antiandrogen monotherapy in the treatment of prostate cancer [J].
Anderson, J .
BJU INTERNATIONAL, 2003, 91 (05) :455-461
[9]   High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: A cross-sectional outpatient study [J].
Angeli, Alberto ;
Guglielmi, Giuseppe ;
Dovio, Andrea ;
Capelli, Giovanni ;
de Feo, Daniela ;
Giannini, Sandro ;
Giorgino, Ruben ;
Moro, Luigi ;
Giustina, Andrea .
BONE, 2006, 39 (02) :253-259
[10]   ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer [J].
Armstrong, Andrew J. ;
Szmulewitz, Russell Z. ;
Petrylak, Daniel P. ;
Holzbeierlein, Jeffrey ;
Villers, Arnauld ;
Azad, Arun ;
Alcaraz, Antonio ;
Alekseev, Boris ;
Iguchi, Taro ;
Shore, Neal D. ;
Rosbrook, Brad ;
Sugg, Jennifer ;
Baron, Benoit ;
Chen, Lucy ;
Stenzl, Arnulf .
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) :2974-+
12345678910